Skip to main content
. 2024 Jul 8;12:1378462. doi: 10.3389/fpubh.2024.1378462

Table 1.

Characteristics of included studies.

Author, year Source of data Source of population Diagnose Age BMI Surgery type Muscle assessment method CT measurement method Total Sample Sample Postoperative outcome
Masashi 2017 Cohort study Japan Sarcopenia 65.5 ± 13.2 21.1 ± 3.5 CABG and Valve surgery CT, gait speed, grip strength, 6MWD SMI n = 773 n = 386 Postoperative all-cause mortality No-sarcopenia 64.4 ± 13.1 23.4 ± 3.5 n = 387
Ikeno 2017 Cohort study Japan Sarcopenia 76.2 ± 5.6 22.5 ± 3.1 Total arch replacement CT, gait speed, grip strength PMI n = 266 n = 81 In-hospital mortality, Discharged to healthcare facility, Length of hospital stay, CRRT require, Atrial fibrillation, Pneumonia, Stroke, Prolonged ventilation No-sarcopenia 75.7 ± 5.7 23.8 ± 2.9 n = 185
Okamura 2018 Cohort study Japan Sarcopenia 77.0 ± 4.6 19.6 ± 2.8 CABG and Valve surgery CT PMA n = 428 n = 107 In-hospital mortality, Discharged to healthcare facility, Length of ICU stay, CRRT require, Atrial fibrillation, Stroke, Prolonged ventilation No-sarcopenia 76.0 ± 4.3 22.6 ± 3.5 n = 321
Robert 2019 Cohort study America Sarcopenia 81 (8) NA Valve surgery CT PMI n = 240 n = 60 Discharged to healthcare facility, Length of hospital stay, Length of ICU stay, CRRT require, Atrial fibrillation, Pneumonia, Wound infection, Stroke, Prolonged ventilation No-sarcopenia 80 (10) NA n = 180
Yamashita 2019 Cohort study Japan Sarcopenia 70 ± 9.6 22.6 ± 4.0 CABG and Valve surgery or Aortic surgery CT, gait speed, grip strength m, 6MWD PMA n = 664 n = 332 Postoperative all-cause mortality No-sarcopenia 61.5 ± 14.0 22.1 ± 3.4 n = 332
Homare 2020 Cohort study Japan Sarcopenia 69.9 ± 8.9 21.6 ± 3.0 CABG CT PMI n = 304 n = 76 In-hospital mortality, Discharged to healthcare facility, Length of ICU stay, CRRT require, Atrial fibrillation, Stroke, Prolonged ventilation No-sarcopenia 66.6 ± 9.7 24.1 ± 3.3 n = 228
Yuriko 2020 Cohort study Japan Sarcopenia 75.1 ± 5.5 22.7 ± 3.4 CABG and Valve surgery CT PMI n = 206 n = 63 In-hospital mortality, Discharged to healthcare facility, Length of hospital stay, Length of ICU stay, CRRT require, Atrial fibrillation, Pneumonia, Wound infection, Stroke No-sarcopenia 73.9 ± 5.5 23.4 ± 3.7 n = 143
Kondo 2021 Cohort study Japan Sarcopenia 81.0 ± 5.8 21.6 ± 4.2 Valve surgery CT PMI n = 140 n = 29 In-hospital mortality, CRRT require, Atrial fibrillation, Wound infection, Stroke, Prolonged ventilation No-sarcopenia 77.3 ± 4.7 22.8 ± 3.7 n = 111
Lee 2021 Cohort study Korea Sarcopenia 72.17 ± 5.46 22.60 ± 2.97 Valve surgery CT SMI n = 874 n = 292 30-day in-hospital events No-sarcopenia 70.67 ± 5.47 25.29 ± 3.04 n = 582
Ikuko 2022 Cohort study Japan Sarcopenia 73.8 ± 8.8 21.5 ± 3.0 CABG and Valve surgery CT, gait speed, grip strength SMI n = 192 n = 72 In-hospital mortality, Discharged to healthcare facility, Length of hospital stay, Length of ICU stay No-sarcopenia 67.0 ± 10.1 24.5 ± 4.3 n = 120
Liu 2022 Cohort study China Sarcopenia 63.5 (18) 19.94 (2.93) Valve surgery CT SMI n = 216 n = 36 In-hospital mortality, Length of hospital stay, Atrial fibrillation, Pneumonia, Wound infection, Stroke, Prolonged ventilation No-sarcopenia 63 (14) 24.29 (3.69) n = 180
Shen 2023 Cohort study China Sarcopenia 67 (10) 22.36 (5.63) CABG CT SMI n = 338 n = 44 In-hospital mortality, Length of hospital stay, Length of ICU stay, CRRT require, Atrial fibrillation, Pneumonia, Wound infection, Stroke, Prolonged ventilation No-sarcopenia 65 (11) 24.95 (3.88) n = 294

The number represents the mean ± standard deviation or median (interquartile range). BMI, body mass index; NA, Not afforded; CABG, coronary artery bypass grafting; PMI, psoas muscle index; SMI, skeletal muscle index; PMA; psoas muscle area; 6MWD, 6-min walking distance; CRRT, Continuous Renal Replacement Therapy; CT, Computed Tomography.